Strategic leadership Recent executive appointments, including a new Chairman and General Counsel, signal a growing corporate governance framework and readiness for larger, more complex partnerships and licensing deals.

Clinical momentum Lead candidate evorpacept is advancing across multiple trials and indications, presenting opportunities for co-development, collaboration, or milestone-driven partnerships with pharmaceutical companies seeking immuno-oncology assets.

Key industry exposure Active participation in major conferences (ESMO Breast Cancer, JP Morgan Healthcare, SITC, AACR-NCI-EORTC) provides access to a wide network of potential collaborators, researchers, and potential licensing or financing discussions.

Financial capacity Significant funding with a strong runway and mid-scale revenue, enabling strategic BD deals, equity financings, or non-dilutive collaboration structures to accelerate trials and expansion into additional indications.

Evidence potential Data generation around CD47 biomarker profiles and potential combination strategies positions ALX Oncology as a partner for biomarker-driven trials and companion diagnostic development with larger biopharma.